2m 2m 2m 2m 2m 2m 2m
C4 THERAPEUTICS (CCCC)
NASDAQ
$2.91-$0.09 (-3.07%)
Price as of Nov 11, 2026 7:30 PM EST- $394.0MMarket Cap
- 20.97%1-Year Change
- BiotechnologyIndustry
C4 THERAPEUTICS (CCCC)
$2.91-$0.09 (-3.07%)
CCCC | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $3.00 | ||
Change | -$0.15 (-4.76%) | ||
Open | $3.11 | ||
High | $3.16 | ||
Low | $2.93 | ||
Previous Close | $3.15 | ||
Volume | 1,453,624 | ||
30-Day Average Volume | 2,982,487 | ||
1-Week Change | -6.54% | ||
1-Month Change | -5.06% | ||
1-Year Change | 20.97% | ||
3-Year Change | 74.42% | ||
5-Year Change | -93.29% | ||
Fundamentals | |||
Shares Outstanding | 131.3M | ||
Total Assets | $331.8M | ||
Market Cap | $394.0M | ||
Enterprise Value | $361.5M | ||
Period: QTR TTM FY | |||
Revenue | $8.5M | ||
Net Income | -$21.8M | ||
Free Cash Flow | -$26.0M | ||
EBIT | -$21.8M | ||
EBITDA | -$21.5M | ||
Net Working Capital | $173.0M | ||
EPS | -$0.16 | ||
Enterprise Value/EBITDA | -17 | ||
Enterprise Value/Revenue | 43 | ||
P/B | 2 | ||
P/E | -19 | ||
PEG | -2 | ||
Price/Free Cash Flow | -15 | ||
Price/Operating Cash Flow | -15 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue